Adjuvant therapy with GnRH agonists/tamoxifen in breast cancer should be a good council for patients with hormone receptor-positive tumours and wish to preserve fertility

Medical Hypotheses

Volumn 78, Issue 4, 2012, Pages 442-445

  Franco Jr , J G ^a,b,c   Oliveira, J B A ^a,b,c   Petersen, C G ^a,b,c   Mauri, A L ^a,b   Baruffi, R ^a,b   Cavagna, M ^a,b  

^a Center for Human Reproduction Prof Franco Jr   (Brazil)

^b Paulista Center for Diagnosis Research and Training   (Brazil)

^c SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; METHOTREXATE; TAMOXIFEN; TRIPTORELIN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ALOPECIA; AMENORRHEA; ARTICLE; BONE DENSITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG WITHDRAWAL; EDEMA; EVENT FREE SURVIVAL; FATIGUE; FEMALE FERTILITY; FOLLOW UP; HOT FLUSH; HUMAN; LEUKOPENIA; MENOPAUSAL SYNDROME; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY FUNCTION; OVERALL SURVIVAL; PREGNANCY; QUALITY OF LIFE; RECURRENCE FREE SURVIVAL; SIDE EFFECT; VAGINA DISCHARGE; VOMITING; WEIGHT GAIN;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INFERTILITY, FEMALE; PREMENOPAUSE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TAMOXIFEN;

EID: 84858155430     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.12.015     Document Type: Article

References (23)

1. Lawrenz B., Neunhoeffer E., Henes M., Lessmann-Bechle S., Kramer B., Fehm T. Management of fertility preservation in young breast cancer patients in a large breast cancer centre. Arch Gynecol Obstet 2010, 282:547-551.
2. Lee M.C., Gray J., Han H.S., Plosker S. Fertility and reproductive considerations in premenopausal patients with breast cancer. Cancer Control 2010, 17:162-172.
3. Poniatowski B.C., Grimm P., Cohen G. Chemotherapy-induced menopause: a literature review. Cancer Invest 2001, 19:641-648.
4. Badawy A., Elnashar A., El-Ashry M., Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009, 91:694-697.
5. Clowse M.E., Behera M.A., Anders C.K., Copland S., Coffman C.J., Leppert P.C., et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt) 2009, 18:311-319.
6. 2008 Assisted Reproductive Technology Success Rates/National Summary and Fertility Clinic Reports/Division of Reproductive Health/National Center for Chronic Disease Prevention and Health Promotion/Centers for Disease Control and Prevention; 2010. http://www.cdc.gov/ART/ART2008.
7. Cobo A., Kuwayama M., Perez S., Ruiz A., Pellicer A., Remohi J. Comparison of concomitant outcome achieved with fresh and cryopreserved donor oocytes vitrified by the cryotop method. Fertil Steril 2008, 89:1657-1664.
8. Grifo J.A., Noyes N. Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients. Fertil Steril 2010, 93:391-396.
9. Sanchez-Serrano M., Novella-Maestre E., Rosello-Sastre E., Camarasa N., Teruel J., Pellicer A. Malignant cells are not found in ovarian cortex from breast cancer patients undergoing ovarian cortex cryopreservation. Hum Reprod 2009, 24:2238-2243.
10. Rosendahl M., Timmermans Wielenga V., Nedergaard L., Kristensen S.G., Erns E., Rasmussen P.E., et al. Cryopreservation of ovarian tissue for fertility preservation: no evidence of malignant cell contamination in ovarian tissue from patients with breast cancer. Fertil Steril 2011, 95:2158-2161.
11. Castiglione-Gertsch M., O'Neill A., Price K.N., Goldhirsch A., Coates A.S., et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2003, 95:1833-1846. International-Breast-Cancer-Study-Group (IBCSG).
12. Schmid P., Untch M., Kosse V., Bondar G., Vassiljev L., Tarutinov V., et al. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. J Clin Oncol 2007, 25:2509-2515.
13. Kaufmann M., Jonat W., Blamey R., Cuzick J., Namer M., Fogelman I., et al. Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 2003, 39:1711-1717.
14. von Minckwitz G., Graf E., Geberth M., Eiermann W., Jonat W., Conrad B., et al. CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93). Eur J Cancer 2006, 42:1780-1788.
15. Bernhard J., Zahrieh D., Castiglione-Gertsch M., Hurny C., Gelber R.D., Forbes J.F., et al. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients - the International Breast Cancer Study Group Trial VIII. J Clin Oncol 2007, 25:263-270.
16. Goel S, Sharma R, Hamilton A, Beith J. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev 2009:CD004562.
17. Jakesz R., Hausmaninger H., Kubista E., Gnant M., Menzel C., Bauernhofer T., et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 2002, 20:4621-4627.
18. Roche H., Kerbrat P., Bonneterre J., Fargeot P., Fumoleau P., Monnier A., et al. Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial. Ann Oncol 2006, 17:1221-1227.
19. Boccardo F., Rubagotti A., Amoroso D., Mesiti M., Romeo D., Sismondi P., et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardohp380.ist.unige.it. J Clin Oncol 2000, 18:2718-2727.
20. Gnant M., Mlineritsch B., Schippinger W., Luschin-Ebengreuth G., Postlberger S., Menzel C., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691.
21. Hershman D.L., McMahon D.J., Crew K.D., Cremers S., Irani D., Cucchiara G., et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008, 26:4739-4745.
22. Gabriel C.A., Domchek S.M. Breast cancer in young women. Breast Cancer Res 2010, 12:212.
23. Cuzick J., Ambroisine L., Davidson N., Jakesz R., Kaufmann M., et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007, 369:1711-1723. LHRH-agonists-in-Early-Breast-Cancer-Overview-group.